DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20191759

PUVAsol therapy in the management of vitiligo: outcome in a dermatology clinic in South-West Nigeria

Patrick O. Echekwube, Olayinka A. Olasode, Emmanuel O. Onayemi

Abstract


Background: Vitiligo is a depigmentary dermatosis which currently has no cure but there are different treatment options available to treat affected patients with varying results. The aim of the study was to ascertain the effect of PUVAsol therapy offered to adult patients with vitiligo at a tertiary hospital in Nigeria.

Methods: All consecutive adult patients with vitiligo who presented at the Obafemi Awolowo University Teaching Hospitals complex, Ile-lfe and gave consent were recruited for the study which was for a period of 6 months. Patients with limited disease were treated with topical PUVAsol and those with extensive disease were treated with oral PUVAsol. The outcome of therapy for the patients was classified into three categories as follows: progressed (P), stable (S) and repigmented (R). The repigmented group was further sub-classified into fair (R1) and good (R2) representing ≤50% and >50% repigmentation of areas affected respectively.

Results: After 6 months of therapy, most of the patients (92%) had repigmentation of their lesions while the remaining had either stable lesions (6%) or progression of their lesions (2%). Amongst the patients whose lesions got repigmented, 96% of them had repigmentation in less than half of the areas affected by vitiligo which was a fair outcome.

Conclusions: PUVAsol is a treatment modality for vitiligo with some repigmentation of lesions following therapy for 6 months. PUVAsol therapy could be recommended in resource poor settings because of its low cost and availability in most parts of Nigeria.


Keywords


Nigeria, PUVAsol, Vitiligo

Full Text:

PDF

References


Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74–84.

Kyriakis KP, Palamaras I, Tsele E. Case detection rates of vitiligo by gender and age. Int J Dermatol. 2009;48:328–9.

Ayanlowo O, Olumide YM, Akinkugbe A. Characteristics of vitiligo in Lagos, Nigeria. West Afr J Med. 2009;28:118–21.

Ezzedine K, Lim HW, Suzuki T. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25:E1-13.

Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003;1:58.

Sangma LN, Nath J, Bhagabati D. Quality of life and psychological morbidity in vitiligo patients: a study in a teaching hospital from north-East India. Indian J Dermatol. 2015;60:142–6.

Lerner AB. On the etiology of vitiligo and gray hair. Am J Med 1971;51:141–7.

Kovacs SO. Vitiligo. J Am Acad Dermatol. 1998;38:647-66.

Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment cell Res. 2003;16:90–100.

Le Poole IC, Das PK, van den Wijngaard RM. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol. 1993;2:145–53.

Gawkrodger DJ, Ormerod AD, Shaw L. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051–76.

Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: A comprehensive overview. J Am Acad Dermatol. 2011;65:493–514.

Allam M, Riad H. Concise review of recent studies in vitiligo. Qatar Med J. 2013;2013:1–19.

Radakovic-Fijan S, Fürnsinn-Friedl AM, Hönigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001;44:814–7.

Parsad D, Kanwar A. Oral minocycline in the treatment of vitiligo - A preliminary study. Dermatol Ther. 2010;23:305–7.

Ortonne JP, Schmitt D, Thivolet J. PUVA-induced repigmentation of vitiligo: scanning electron microscopy of hair follicles. J Invest Dermatol. 1980;74:40–2.

Fa Y, Lin Y, Chi XJ. Treatment of vitiligo with 308-nm excimer laser: our experience from a 2-year follow-up of 979 Chinese patients. J Eur Acad Dermatology Venereol. 2017;31:337–40.

Handa S, Pandhi R, Kaur I. Vitiligo: a retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol. 2001;28:461–6.

Shenoi SD, Prabhu S. Indian Association of Dermatologists, Venereologists and Leprologists. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol. 2014;80:497–504.

Anbar TS, El-Sawy AE, Attia SK. Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: histopathological, immuno-histochemical and ultrastructural study. Photodermatol Photoimmunol Photomed. 2012;28:17–25.

Lee D-Y, Kim C-R, Park J-H, Lee J-H. The incidence of leukotrichia in segmental vitiligo: implication of poor response to medical treatment. Int J Dermatol. 2011; 50:925–7.